You've just added:

Home / News

News + Media

April 13, 2016

Charles River Laboratories and BioMotiv Enter Into Strategic Partnership

WILMINGTON, MA, April 13, 2016 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Through this partnership, Charles River will... Continue Reading

March 15, 2016

Harrington Discovery Institute and The American Society for Clinical Investigation honor Jeffery M. Friedman, MD, PhD

CLEVELAND – The third annual Harrington Prize for Innovation in Medicine has been awarded to Jeffrey M. Friedman, MD, PhD, of The Rockefeller University, New York City, for his discovery of leptin and the leptin-mediated pathway that controls feeding behavior.The Harrington Prize for Innovation in Medicine, established in... Continue Reading

February 29, 2016

Harrington Scholar-Innovator Darren Carpizo Launches Z53 Therapeutics, a New Oncology Start-Up Combating Cancer-Associated Mutation

Formed by BioMotiv and Rutgers UniversityCLEVELAND AND NEW BRUNSWICK— FEBRUARY 29, 2016— BioMotiv, a drug development accelerator associated with The Harrington Project, and Rutgers, the State University of New Jersey, are announcing the formation of a new biotechnology startup, Z53 Therapeutics. Z53 Therapeutics aims to... Continue Reading

January 13, 2016

Announcing our 2016 Harrington Scholar-Innovator Award Recipients

Cleveland, Ohio – The Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio has announced the 2016 recipients of Harrington Scholar-Innovator Awards. The awards support breakthrough work of physician-scientists whose discovery research shows promise of advancing the standard of care.The Harrington... Continue Reading

January 08, 2016

Harrington Distinguished Scholar Announces Company Collaboration with Bristol-Myers Squibb

Cleveland– January 8, 2016 – Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases. Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer... Continue Reading